This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Data From Clinical Trials Show Pluristem’s Placenta-Derived Cell Therapy Is Safe And Improves Quality Of Life And Efficacy Measurements In Patients With Critical Limb Ischemia

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today reported that data from clinical trials show the Company’s placenta-derived cell therapy, PLX-PAD, is safe and improves quality of life as well as other efficacy measurements in patients with Critical Limb Ischemia (CLI), the end-stage of Peripheral Artery Disease (PAD).

CLI Patients and Doctors Involved in Trials Share Their Stories on Video; CLICK HERE to Watch

The three-month follow-up data involved 21 patients afflicted with CLI in two open-label, dose-escalation, Phase I clinical trials conducted at Duke University Medical Center, Stanford University Medical Center, the Center for Therapeutic Angiogenesis in Birmingham, Alabama and St. Franziskus Hospital, supported by the Charité - University Medicine Berlin. The results of these clinical trials have enabled Pluristem to select the target treatment dose of PLX-PAD for additional studies focused on the cell therapy’s efficacy. Pluristem has communicated with both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) concerning the design of an optimal multinational study that will support an approval for marketing PLX-PAD for the treatment of CLI.

The two Phase I studies were designed to evaluate the safety of PLX-PAD cells and included accessing the patient’s immunological profile before and after the local administration of PLX-PAD. In addition, efficacy parameters were assessed and five different doses of PLX-PAD were evaluated. These studies were performed in parallel in the EU and USA and represent the first time that Pluristem’s PLX-PAD cells were administered to humans. PLX-PAD cells are derived from human placenta, a non-controversial, non-embryonic, adult stem cell source.

Results included the findings that PLX-PAD cells can be administered safely as an “off-the-shelf” product without a need for matching between donor and patient. Additionally, efficacy was demonstrated across all doses with a statistically significant improvement noted in the pain score and quality of life. The intermediate dose also showed a statistically significant improvement in the Ankle Brachial Index (ABI), a measure of blood flow.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
PSTI $1.88 0.00%
AAPL $110.37 0.00%
FB $88.15 0.00%
GOOG $606.25 0.00%
TSLA $245.57 0.00%

Markets

Chart of I:DJI
DOW 16,374.76 +23.38 0.14%
S&P 500 1,951.13 +2.27 0.12%
NASDAQ 4,733.4970 -16.4820 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs